Waldenström's macroglobulinemia differential diagnosis: Difference between revisions
No edit summary |
|||
| Line 7: | Line 7: | ||
==Differentiating Waldenström's macroglobulinemia from other B cell lymphoid neoplasms== | ==Differentiating Waldenström's macroglobulinemia from other B cell lymphoid neoplasms== | ||
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref><ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref> | Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:<ref name="UTD">Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015</ref><ref name="pubM">{{cite journal |vauthors=Sahin I, Leblebjian H, Treon SP, Ghobrial IM |title=Waldenström macroglobulinemia: from biology to treatment |journal=Expert Rev Hematol |volume=7 |issue=1 |pages=157–68 |year=2014 |pmid=24405328 |doi=10.1586/17474086.2014.871494 |url=}}</ref> | ||
Revision as of 18:59, 17 November 2015
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mirdula Sharma, MBBS [2]
|
Waldenström's macroglobulinemia Microchapters |
|
Differentiating Waldenström's macroglobulinemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Waldenström's macroglobulinemia differential diagnosis On the Web |
|
American Roentgen Ray Society Images of Waldenström's macroglobulinemia differential diagnosis |
|
FDA on Waldenström's macroglobulinemia differential diagnosis |
|
CDC on Waldenström's macroglobulinemia differential diagnosis |
|
Waldenström's macroglobulinemia differential diagnosis in the news |
|
Blogs on Waldenström's macroglobulinemia differential diagnosis |
|
Directions to Hospitals Treating Waldenström's macroglobulinemia |
|
Risk calculators and risk factors for Waldenström's macroglobulinemia differential diagnosis |
Overview
Waldenström's macroglobulinemia must be differentiated from Multiple myeloma, Chronic lymphocytic leukemia/small lymphocytic lymphoma, B-cell prolymphocytic leukemia, Follicular lymphoma, Mantle cell lymphoma, and Marginal zone lymphoma.[1][2]
Differentiating Waldenström's macroglobulinemia from other B cell lymphoid neoplasms
Waldenström's macroglobulinemia must be differentiated from other B cell lymphoid neoplasms including:[1][2]
- Always express CD5, usually CD23 positive
- Express bright surface IgM, CD20 and other B-cell antigens (CD19, CD22, CD79a, FMC7)
- Express CD10, HLA-DR, pan B-cell antigens (CD19, CD20, CD79a), CD21, and surface IgM, IgG, or IgA
- Bone marrow infiltration of small, cleaved cells that are usually paratrabecular
- Rearrangement of Bcl-2
- Express CD138, CD38, CD79a, and VS38c and CD56(70%)
- Presence of Plasmacytic cell infiltration of bone marrow, osteolytic lesions and renal insufficiency
- Translocation involving chromosome 11 (t11;14)
- Express CD5+ and CD23-, surface IgM and IgD and cyclin D1 in majority of cases
- Infiltration of bone marrow by monomorphous, small lymphoid cells with irregular nuclei
- Marginal zone lymphoma:
- Expresses B cell markers CD19, CD20, and CD22
- Infiltrates the bone marrow with a characteristic intertrabecular and intrasinusoidal pattern
- Most common cytogenetic abnormalities are loss of 7q (19%) along with +3q (19%) and +5q (10% )
References
- ↑ 1.0 1.1 Clinical manifestations, pathologic features, and diagnosis of lymphoplasmacytic lymphoma. UpToDate (2015)http://www.uptodate.com/contents/clinical-manifestations-pathologic-features-and-diagnosis-of-lymphoplasmacytic-lymphoma?source=see_link§ionName=PATHOGENESIS&anchor=H198194648#H198194648 Accessed on November 9, 2015
- ↑ 2.0 2.1 Sahin I, Leblebjian H, Treon SP, Ghobrial IM (2014). "Waldenström macroglobulinemia: from biology to treatment". Expert Rev Hematol. 7 (1): 157–68. doi:10.1586/17474086.2014.871494. PMID 24405328.